Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vivitrol (Extended Release Naltrexone) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

NCT05043766
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF614, Naltrexone Hydrochloride, OxyContin
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

NCT01999946
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Extended-Release Naltrexone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

NCT01822132
View directory record Official record
Conditions
Methamphetamine Abuse, HIV
Interventions
Extended release naltrexone, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 29, 2026, 2:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023
View directory record Official record
Conditions
Drug Dependence
Interventions
Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 21 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone

NCT02617628
View directory record Official record
Conditions
Opiate Dependence
Interventions
extended release naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

NCT05053503
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Device · Drug
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rancho Mirage, California • Crownsville, Maryland • Center City, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

NCT02978417
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone for extended-release injectable suspension, Oral naltrexone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

Alcohol Disorder hOsPital Treatment Trial

NCT02478489
View directory record Official record
Conditions
Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder
Interventions
Oral naltrexone (PO-NTX), Extended-release injectable naltrexone (XR-NTX)
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)

NCT01449565
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

NCT00511836
View directory record Official record
Conditions
Alcohol Dependence
Interventions
VIVITROL 380 mg, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

NCT02445339
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorder
Interventions
XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 29, 2026, 2:14 PM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 29, 2026, 2:14 PM EDT
Completed No phase listed Observational

Reducing Overdose After Release From Incarceration

NCT03902821
View directory record Official record
Conditions
Overdose, Drug
Interventions
XR-NTX and Certified Recovery Mentor
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Wilsonville, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 29, 2026, 2:14 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional

Biomarkers of Injectable Extended Release Naltrexone Treatment

NCT02324725
View directory record Official record
Conditions
Heroin Dependence, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study

NCT01908062
View directory record Official record
Conditions
Opioid Use Disorder, Alcohol Use Disorder
Interventions
Extended Release Naltrexone, Treatment As usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 29, 2026, 2:14 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 29, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

NCT04454411
View directory record Official record
Conditions
Opioid Dependence
Interventions
Brixadi, Vivitrol
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone

NCT03306368
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Youth Opioid Recovery Support
Behavioral
Lead sponsor
Potomac Health Foundations
Other
Eligibility
18 Years to 26 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence

NCT01690546
View directory record Official record
Conditions
Opiate Dependence
Interventions
very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
Drug
Lead sponsor
Paolo Mannelli
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

NCT05262270
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX, Placebo (PLB) Injectable matched to XR-BUP
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 29, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 29, 2026, 2:14 PM EDT